Literature DB >> 19082465

Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1.

A Stebel1, C Brachetti, M Kunkel, M Schmidt, G Fritz.   

Abstract

In this study, we investigated the expression level of Ras-homologous (Rho) GTPases and the Rho guanine exchange factor (GEF) T-cell lymphoma invasion and metastasis 1 (Tiam1) in breast tumor specimens (n=106) by immunohistochemistry. Rho and Rho-GEF expression scores were compared to clinically established diagnostic and prognostic parameters. We found that RhoA and RhoB scores slightly increased with tumor grade, whereas the Rac1 score remained unaffected. The most significant effects were observed for the Rac1-specific GEF Tiam1. Tiam1 expression scores significantly decreased with the increase in tumor grade, tumor spreading and proliferation. Furthermore, Tiam1 expression was inversely related to the plasminogen activator inhibitor (PAI-1) and estrogen receptor (ER) expression but not the progesterone receptor (PR) and urokinase plasminogen activator (uPA). A low Tiam1 expression was associated with p53 positivity without being related to HER2/neu status. The data show that Tiam1 expression decreases with the progression of breast carcinomas and is inversely associated with several established breast tumor markers. Therefore, we suggest that Tiam1 counteracts the progression of breast carcinomas and is suitable as a novel breast tumor marker.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19082465

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  Opposite functions of STAT3 and Smad3 in regulating Tiam1 expression in Th17 cells.

Authors:  Thomas Buttrick; Samia J Khoury; Wassim Elyaman
Journal:  Small GTPases       Date:  2017-09-18

2.  Rac1 GTPase-deficient HeLa cells present reduced DNA repair, proliferation, and survival under UV or gamma irradiation.

Authors:  Gisele Espinha; Juliana H Osaki; Yuli T Magalhaes; Fabio Luis Forti
Journal:  Mol Cell Biochem       Date:  2015-03-11       Impact factor: 3.396

Review 3.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

4.  Clinical value of Tiam1-Rac1 signaling in primary gallbladder carcinoma.

Authors:  Xilin Du; Shengzhi Wang; Jianguo Lu; Qing Wang; Nuan Song; Tao Yang; Rui Dong; Li Zang; Yuan Yang; Tao Wu; Chengguo Wang
Journal:  Med Oncol       Date:  2011-08-19       Impact factor: 3.064

Review 5.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

Review 6.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

Review 7.  Rac signaling in breast cancer: a tale of GEFs and GAPs.

Authors:  Eva Wertheimer; Alvaro Gutierrez-Uzquiza; Cinthia Rosemblit; Cynthia Lopez-Haber; Maria Soledad Sosa; Marcelo G Kazanietz
Journal:  Cell Signal       Date:  2011-08-27       Impact factor: 4.315

8.  RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Authors:  Emilie Malissein; Elise Meunier; Isabelle Lajoie-Mazenc; Claire Médale-Giamarchi; Florence Dalenc; Sophie F Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-06       Impact factor: 4.553

9.  The Tiam1 guanine nucleotide exchange factor is auto-inhibited by its pleckstrin homology coiled-coil extension domain.

Authors:  Zhen Xu; Lokesh Gakhar; Fletcher E Bain; Maria Spies; Ernesto J Fuentes
Journal:  J Biol Chem       Date:  2017-09-07       Impact factor: 5.157

Review 10.  Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease.

Authors:  D R Cook; K L Rossman; C J Der
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.